The company’s initial investors, Flagship Ventures, Polaris Venture Partners and Flybridge Capital Partners were joined by new investors Partners Healthcare and In-Q-Tel in the round. T2 Biosystems has
The agreement represents the first occasion of services being offered through Innovent Oncology, which will work with Rocky Mountain Cancer Centers (RMCC) to support Colorado Public Employees’ Retirement
Under the agreement, Hewlett-Packard Company (HP) will license its intellectual property to Home Dialysis Plus (HD+) in return for royalty payments. HD+ will develop, manufacture and sell the
This agreement expands InteGreat’s existing agreement with Nuance, giving InteGreat the ability to provide its clients with Dragon Medical 10, a real-time medical speech recognition software. Dragon Medical
Under the terms of the agreement, Valeant received an upfront payment of $125 million from GlaxoSmithKline (GSK). Valeant develops, manufactures and markets a broad range of pharmaceutical products
Through this collaboration, Glycotex and Advanced Medical Solutions (AMS) have agreed to an initial phase of testing of the use of GLYC-101 with AMS’s wound dressings. Under the
The Phase I trial is a randomized, placebo-controlled single-dose, dose-escalating study to evaluate the safety and pharmacokinetics of ACE-031. This clinical trial is the first-in-human study in the
Additionally, following key court rulings in favor of Celebrex, claims regarding Celebrex, a pain treatment, will also be resolved as part of the settlement. The announcement follows favorable
Accordingly, Ranbaxy has become a subsidiary of Daiichi Sankyo. Ranbaxy has now received through the preferential issue of equity shares and warrants an amount of $736 million from
The Central Designer technology provides one central and independent environment for building studies, where all teams work within a centralized system and one that allows for reuse of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.